Cristian Rodriguez-Aguayo, Ph.D.
Department of Gyn Onc&Reproductive Med-Rsch, Division of Surgery Division
About Dr. Cristian Rodriguez-Aguayo
Cristian Rodriguez-Aguayo, BS, MS, Ph.D. is an Instructor, RFA, Experimental Therapeutics Department at MD Anderson Cancer Center, Houston, TX, USA. He received his BS. degree in Biopharmacology. Universidad Autónoma de Nayarit, Tepic, Nayarit, México, and after he obtained M.S. in Morphology, Universidad Autónoma de Nuevo León (UANL), Monterrey, Nuevo León, México. After getting his M.S., Rodriguez-Aguayo completed his Ph.D. in Infectomics and Molecular Pathogenesis, Centro de Investigación y Estudios Avanzados (CINVESTAV) del Instituto Politécnico Nacional (IPN), Mexico D.F., Mexico and post doc training in the Experimental Therapeutics Department at MD Anderson. Rodriguez’s research focuses in three main areas: 1) Development of new strategies for systemic in vivo Non-Coding-RNA delivery using biocompatible nanoparticles; 2) Chemo-resistance mechanism on ovarian cancer growth and progression; and 3) Development of novel anti-RBP’s and Non-Coding-RNAs therapeutic approaches. His main goal is to continue a career in translational cancer research to identify effective therapeutic targets for development of more effective therapeutic strategies. His current research focuses on the understanding of the functional basis and biological mechanism by RBPs and non-coding RNAs promote cancer growth and tumor progression.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Instructor, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Nanocarriers, Liposomes, siRNA, miRNA, RNA binding proteins (RBPs), Drug resistances
Clinical Interests
My main
goal is to continue a career in translational cancer research to identify
effective therapeutic targets for development of more effective therapeutic
strategies.
Education & Training
Degree-Granting Education
| 2012 | Center for Research and Advanced Studies (CINVESTAV), National Polytechnic Institute, Cuidad de Mexico, DF, MX, Infectomics and Molecular Pathogensis, Ph.D |
| 2007 | Universidad Autonoma de Nuevo Leon, San Nicolas de los Garza, MX, Morphology, M.S |
| 2004 | Universidad Autonoma de Nayarit, Tepic, MX, Biopharmaceutical Chemistry, BA |
Postgraduate Training
| 2012-2016 | Research Fellowship, Cancer Biology and Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas |
Licenses & Certifications
| 2008 | Morphology |
| 2005 | Biopharmaceutical Chemistry |
Experience & Service
Faculty Academic Appointments
Instructor, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2023
Editorial Activities
Editor, Medical Science, 2010 - Present
Honors & Awards
| 2018 - 2019 | The Boazman Distinguished Young Scientist International, The University of Texas MD Anderson Cancer Center |
| 2018 | Travel Award of Non-coding RNA Journal, Non-Coding RNA Journal, MPDI Editorial Group |
| 2017 | Barnhart Award in Targeted Therapies, The University of Texas MD Anderson Cancer Center |
| 2016 - 2020 | National Research System Level 1, National Council of Science and Technology (CONACYT) |
| 2014 | Texas Center for Cancer Nanomedicine (TCCN) research awards, The University of Texas MD Anderson Cancer Center |
| 2013 - 2016 | National Research System Level 1, National Council of Science and Technology (CONACYT) |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2015. “hnRNP A1 Regulation by MicroRNAs Control the MIR18a:K-RAS Axis in Chemotherapy Resistant Ovarian Cancer”. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
National Presentations
- 2014. “In vivo efficacy of Silicon Particles Incorporating Liposomal EphA2 siRNA in Preclinical Ovarian Cancer Models”. Conference. American Association for Cancer Research (AACR). SAN DIEGO, CA, US.
- 2013. Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane-Resistant Ovarian Cancer. Conference. American Association for Cancer Research (AACR). Washington, DC, US.
- 2012. Multistage Vectored siRNA Therapeutics for the Treatment of Ovarian Cancer. Conference. NCI Alliance for Nanotechnology in Cancer. HOUSTON, TX, US.
- 2011. Multistage Vectored siRNA Therapeutics for the Treatment of Ovarian Cancer. Conference. American Association for Cancer Research (AACR). Orlando, FL, US.
- 2010. c-Jun-NH2-kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer. Conference. American Association for Cancer Research (AACR). Washington, DC, US.
Formal Peers
- 2010. c-Jun-NH2-kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer. Invited. Tepic, MX.
Grant & Contract Support
| Date: | 2025 - 2028 |
| Title: | Mechanism-Based Targeting of Wild-Type p53 in Refractory Ovarian Cancer |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RP260251 |
| Date: | 2025 - 2027 |
| Title: | Priming refractory ovarian cancer for synthetic lethal interactions with PARP inhibitors |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21CA307903-01 |
| Date: | 2025 - 2030 |
| Title: | Maximizing the Anti-Tumor Immune Response in Pediatric High-Grade Glioma Through Immunovirotherapy and RNF2 Inhibition |
| Funding Source: | V Foundation |
| Role: | Co-I |
| ID: | FP00026891 |
| Date: | 2025 - 2028 |
| Title: | INTERCEPT Platform for In Vivo Immune Engineering Through Epigenetic Editing |
| Funding Source: | W. M. KECK Foundation |
| Role: | Co-I |
| ID: | FP00025550 |
| Date: | 2024 - 2029 |
| Title: | Harnessing the Power of Artificial Intelligence to uncover new targets and potential impact of nanomedical treatments in prolonging Ovarian Cancer patient response and survival |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA283899-01A1 |
| Date: | 2024 - 2029 |
| Title: | Harnessing the Power of Artificial Intelligence to uncover new targets and potential impact of nanomedical treatments in prolonging Ovarian Cancer patient response and survival |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA283899-01A1 |
| Date: | 2024 - 2029 |
| Title: | Precision Epigenomic Nanoengineered System (PENS) to Circumvent T-cell Exhaustion in High-grade Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1R01CA288606-01 |
| Date: | 2024 - 2026 |
| Title: | Utility of PARP Inhibitors in Rare Refractory Ovarian Cancer Sub-Types |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21CA288797-01 |
| Date: | 2024 - 2026 |
| Title: | Novel Strategies for CRISPR-dCAS9/gRNA Delivery in Developing Targeted Epigenetic Cancer Therapy |
| Funding Source: | Institutional Research Grant (IRG) |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | Targeted epigenetic therapy to overcome T-Cell exhaustion in ovarian cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R21CA290281-01 |
| Date: | 2024 - 2026 |
| Title: | Aptamer-siRNA chimeras Targeted Therapy of Pediatric Medulloblastoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | GRANT13914924 |
| Date: | 2024 - 2027 |
| Title: | Targeted epigenetic therapy to overcome T-Cell exhaustion in ovarian cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP240325 |
| Date: | 2024 - 2027 |
| Title: | Aptamer-siRNA chimeras Targeted Therapy of Pediatric Medulloblastoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP240150 |
| Date: | 2024 - 2024 |
| Title: | Targeted epigenetic therapy to overcome T-Cell exhaustion in ovarian cancer |
| Funding Source: | Worldwide Cancer Research |
| Role: | PI |
| Date: | 2023 - 2028 |
| Title: | Use of nanotechnology to understand the ovarian tumor microenvironment to develop effective treatment strategies |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1R01CA287729-01 |
| Date: | 2023 - 2025 |
| Title: | Targeting MDM4 in Rare Refractory Ovarian Cancer Sub-Types |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | GRANT13803145 |
| Date: | 2023 - 2028 |
| Title: | PR221310: Therapeutics Aptamers for SARS-CoV-2 Treatment |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | GRANT13626713 |
| Date: | 2023 - 2028 |
| Title: | Overcoming T-Cell Exhaustion by Demethylation of TIM3 3’UTR |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA277995-01A1 |
| Date: | 2023 - 2028 |
| Title: | Unmasking Conserved Phospho-Sites for Wild-type p53 Activation in Refractory Cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA279055-01 |
| Date: | 2022 - 2027 |
| Title: | Nanoengineered Genome Editing for Cancer Therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA277995-01 |
| Date: | 2022 - 2024 |
| Title: | Nanoengineered genome editing for cancer therapy |
| Funding Source: | MDACC Adverse Bridge Funding |
| Role: | Co-I |
| Date: | 2022 - 2027 |
| Title: | Nanotechnology intervention to overcome T-cell exhaustion in ovarian cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA284129-01 |
| Date: | 2021 - 2026 |
| Title: | EPHARNA: A Non-Coding RNA Therapeutic for Gynecologic Cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 U01 |
| Date: | 2021 - 2022 |
| Title: | Aptamer Targeted Therapy of Pediatric Brain Tumors |
| Funding Source: | B*Cured |
| Role: | Co-I |
| Date: | 2021 - 2026 |
| Title: | Nanoengineered Genome Editing for Cancer Therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA263892-01 |
| Date: | 2021 - 2022 |
| Title: | Aptamer Targeted Therapy of Pediatric Brain Tumors |
| Funding Source: | Adverse Bridge Funding |
| Role: | Co-I |
| Date: | 2020 - 2025 |
| Title: | Bioengineering Genome Editing for Precision Cancer Immune Therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA253195-01 |
| Date: | 2019 - 2021 |
| Title: | Targeted Therapeutics for Ovarian Cancer and Its Microenvironment - Treatment and Theoretical Modeling |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 3U01CA213759-02 (Admin Supp) |
| Date: | 2017 - 2020 |
| Title: | Novel Approaches for CRISPR CAS9/gRNA Delivery |
| Funding Source: | MD Anderson SPORE |
| Role: | PI |
| Date: | 2017 - 2023 |
| Title: | Targeted Therapeutics for Ovarian Cancer and its Microenvironment - Treatment and Theoretical Modeling |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1U01CA213759-05 (NCE) |
Selected Publications
Peer-Reviewed Articles
- Bueno-Rojas, DA, Bueno-Rojas, JA, Rodriguez-Aguayo, C, Calderón-Santoyo, M, Zamora-Gasga, VM, Montalvo-González, E, García-Magaña, ML. Development of kombucha beverage with jackfruit leaves (Artocarpus heterophyllus Lam) and/or soursop leaves (Annona muricata). Food Chemistry 469, 2025. e-Pub 2025. PMID: 39729659.
- Corvigno, S, Liu, Y, Bayraktar, E, Stur, E, Bayram, NN, Ahumada, AL, Nagaraju, S, Rodriguez-Aguayo, C, Chen, H, Vu, TC, Wen, Y, Liang, H, Zhao, L, Lee, S, Lopez Berestein, G, Sood, AK. Enhanced plant-derived vesicles for nucleotide delivery for cancer therapy. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 38582949.
- Czopik, A, McNamee, EN, Vaughn, V, Huang, X, Bang, IH, Clark, T, Wang, Y, Ruan, W, Nguyen, T, Masterson, JC, Tak, E, Frank, S, Collins, CB, Li, H, Rodriguez-Aguayo, C, Lopez Berestein, G, Gerich, ME, Furuta, GT, Yuan, X, Sood, AK, De Zoeten, EF, Eltzschig, H. HIF-2α-dependent induction of miR-29a restrains TH1 activity during T cell dependent colitis. Nature communications 15(1), 2024. e-Pub 2024. PMID: 39271652.
- Romero-Garay, MG, Montalvo-González, E, Saucedo-Cárdenas, O, Becerra-Verdín, EM, Soto-Domínguez, A, Rodriguez-Aguayo, C, García-Magaña, ML. Hydrolysates of Chicken Byproducts and Their Effect on the Histological and Histopathological Analysis of Liver and Kidney in a Murine Model of Induced Metabolic Syndrome. Biologics 4(3):345-363, 2024. e-Pub 2024.
- Joseph, R, Dasari, SK, Umamaheswaran, S, Mangala, LS, Bayraktar, E, Rodriguez-Aguayo, C, Wu, Y, Nguyen, N, Powell, RT, Sobieski, M, Liu, Y, Kim, MS, Corvigno, S, Foster, KI, Hanjra, P, Vu, TC, Chowdhury, MA, Amero, P, Stephan, C, Lopez Berestein, G, Westin, SN, Sood, AK. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. International journal of molecular sciences 25(2), 2024. e-Pub 2024. PMID: 38279277.
- Dragomir MP, Fuentes-Mattei E, Winkle M, Okubo K, Bayraktar R, Knutsen E, Qdaisat A, Chen M, Li Y, Shimizu M, Pang L, Liu K, Liu X, Anfossi S, Zhang H, Koch I, Tran AM, Mohapatra S, Ton A, Kaplan M, Anderson MW, Rothfuss SJ, Silasi R, Keshari RS, Ferracin M, Ivan C, Rodriguez-Aguayo C, Lopez-Berestein G, Georgescu C, Banerjee PP, Basar R, Li Z, Horst D, Vasilescu C, Bertilaccio MTS, Rezvani K, Lupu F, Yeung SC, Calin GA. Anti-miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response. J Clin Invest 133(14), 2023. e-Pub 2023. PMID: 37261908.
- Liu Y, Ahumada AL, Bayraktar E, Schwartz P, Chowdhury M, Shi S, Sebastian MM, Khant H, de Val N, Bayram NN, Zhang G, Vu TC, Jie Z, Jennings NB, Rodriguez-Aguayo C, Swain J, Stur E, Mangala LS, Wu Y, Nagaraju S, Ermias B, Li C, Lopez-Berestein G, Braam J, Sood AK. Enhancing oral delivery of plant-derived vesicles for colitis. J Control Release 357:472-483, 2023. e-Pub 2023. PMID: 37031740.
- Ramos-Gonzalez MR, Vazquez-Garza E, Garcia-Rivas G, Rodriguez-Aguayo C, Chavez-Reyes A. Therapeutic Effects of WT1 Silencing via Respiratory Administration of Neutral DOPC Liposomal-siRNA in a Lung Metastasis Melanoma Murine Model. Noncoding RNA 9(2), 2023. e-Pub 2023. PMID: 36960966.
- Dasari SK, Joseph R, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AK. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci 24(4), 2023. e-Pub 2023. PMID: 36835335.
- Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]. EBioMedicine 83:104194, 2022. e-Pub 2022. PMID: 35914489.
- Nolasco-González, Y, Chacón-López, MA, Ortiz-Basurto, RI, Aguilera-Aguirre, S, González-Aguilar, GA, Rodriguez-Aguayo, C, Navarro-Cortez, MC, García-Galindo, HS, García-Magaña, ML, Meza-Espinoza, L, Montalvo-González, E. Annona muricata Leaves as a Source of Bioactive Compounds. Horticulturae 8(7), 2022. e-Pub 2022.
- Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Carrami EM, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA. Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 13(1):3352, 2022. e-Pub 2022. PMID: 35688808.
- Lamhamedi-Cherradi SE, Maitituoheti M, Menegaz BA, Krishnan S, Vetter AM, Camacho P, Wu CC, Beird HC, Porter RW, Ingram DR, Ramamoorthy V, Mohiuddin S, McCall D, Truong DD, Cuglievan B, Futreal PA, Velasco AR, Anvar NE, Utama B, Titus M, Lazar AJ, Wang WL, Rodriguez-Aguayo C, Ratan R, Livingston JA, Rai K, MacLeod AR, Daw NC, Hayes-Jordan A, Ludwig JA. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nat Commun 13(1):3057, 2022. e-Pub 2022. PMID: 35650195.
- Attia YM, Salama SA, Shouman SA, Ivan C, Elsayed AM, Amero P, Rodriguez-Aguayo C, Lopez-Berestein G. Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer. Pharmacol Rep 74(2):366-378, 2022. e-Pub 2022. PMID: 35000145.
- Handley KF, Rodriguez-Aguayo C, Ma S, Stur E, Joseph R, Bayraktar E, Dasari SK, Nguyen N, Powell RT, Sobieski M, Ivan C, Kim M, Umamaheswaran S, Glassman D, Wen Y, Amero P, Stephan C, Coleman RL, Landesman Y, Westin SN, Ram PT, Sood AK. Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther 20(12):2352-2361, 2021. e-Pub 2021. PMID: 34583979.
- George J, Li Y, Kadamberi IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen C, Ghosh C, Sun Y, Mittal S, Ramchandran R, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Leone G, Rader JS, Sood AK, Dey M, Pradeep S, Chaluvally-Raghavan P. RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. Cell Rep 37(5):109934, 2021. e-Pub 2021. PMID: 34731628.
- Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X. Author Correction: TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 597(7875):E6, 2021. e-Pub 2021. PMID: 34433970.
- Ma S, Mangala LS, Hu W, Bayaktar E, Yokoi A, Hu W, Pradeep S, Lee S, Piehowski PD, Villar-Prados A, Wu SY, McGuire MH, Lara OD, Rodriguez-Aguayo C, LaFargue CJ, Jennings NB, Rodland KD, Liu T, Kundra V, Ram PT, Ramakrishnan S, Lopez-Berestein G, Coleman RL, Sood AK. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep 36(7):109549, 2021. e-Pub 2021. PMID: 34407412.
- Chakraborty D, Ivan C, Amero P, Khan M, Rodriguez-Aguayo C, Basagaoglu H, Lopez-Berestein G. Explainable Artificial Intelligence Reveals Novel Insight into Tumor Microenvironment Conditions Linked with Better Prognosis in Patients with Breast Cancer. Cancers (Basel) 13(14), 2021. e-Pub 2021. PMID: 34298668.
- Amero P, Lokesh GLR, Chaudhari RR, Cardenas-Zuniga R, Schubert T, Attia YM, Montalvo-Gonzalez E, Elsayed AM, Ivan C, Wang Z, Cristini V, Franciscis V, Zhang S, Volk DE, Mitra R, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G. Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity. J Am Chem Soc 143(20):7655-7670, 2021. e-Pub 2021. PMID: 33988982.
- Gao C, Jin G, Forbes E, Mangala LS, Wang Y, Rodriguez-Aguayo C, Amero P, Bayraktar E, Yan Y, Lopez-Berestein G, Broaddus RR, Sood AK, Xue F, Zhang W. Inactivating Mutations of the IK Gene Weaken Ku80/Ku70-Mediated DNA Repair and Sensitize Endometrial Cancer to Chemotherapy. Cancers (Basel) 13(10), 2021. e-Pub 2021. PMID: 34065218.
- Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight 6(7), 2021. e-Pub 2021. PMID: 33793423.
- Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 6(7), 2021. e-Pub 2021. PMID: 33793425.
- Elsayed AM, Bayraktar E, Amero P, Salama SA, Abdelaziz AH, Ismail RS, Zhang X, Ivan C, Sood AK, Lopez-Berestein G, Rodriguez-Aguayo C. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. Int J Mol Sci 22(4):1-25, 2021. e-Pub 2021. PMID: 33668685.
- Sasano, T, Cho, MS, Rodriguez-Aguayo, C, Bayraktar, E, Taki, M, Afshar-Kharghan, V, Sood, AK. Role of tissue-factor bearing extracellular vesicles released from ovarian cancer cells in platelet aggregation in vitro and venous thrombosis in mice. Thrombosis Update 2, 2021. e-Pub 2021.
- Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, Ivan C, Cho MS, Bayraktar E, Rodriguez-Aguayo C, Dasari SK, Stur E, Mangala LS, Lopez-Berestein G, Sood AK. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene 40(2):384-395, 2021. e-Pub 2021. PMID: 33149280.
- Mangala LS, Rodriguez-Aguayo C, Bayraktar E, Jennings NB, Lopez-Berestein G, Sood AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol 2372:157-168, 2021. e-Pub 2021. PMID: 34417750.
- Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G. Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. RNA Biol 17(11):1-12, 2020. e-Pub 2020. PMID: 31847695.
- Pichler M, Rodriguez-Aguayo C, Nam SY, Dragomir MP, Bayraktar R, Anfossi S, Knutsen E, Ivan C, Fuentes-Mattei E, Lee SK, Ling H, Catela Ivkovic T, Huang G, Huang L, Okugawa Y, Katayama H, Taguchi A, Bayraktar E, Bhattacharya R, Amero P, He WR, Tran AM, Vychytilova-Faltejskova P, Klec C, Bonilla DL, Zhang X, Kapitanovic S, Loncar B, Gafà R, Wang Z, Cristini V, Hanash SM, Bar-Eli M, Lanza G, Slaby O, Goel A, Rigoutsos I, Lopez-Berestein G, Calin GA. Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer. Gut 69(10):1818-1831, 2020. e-Pub 2020. PMID: 31988194.
- Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Correction: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 26(18):5050, 2020. e-Pub 2020. PMID: 32934031.
- Miyake TM, Pradeep S, Bayraktar E, Stur E, Handley KF, Wu SY, Rodriguez-Aguayo C, Lee JS, Lopez-Berestein G, Coleman RL, Sood AK. NRG1/ERBB3 pathway activation induces acquired resistance to XPO1 inhibitors. Mol Cancer Ther 19(8):1727-1735, 2020. e-Pub 2020. PMID: 32499298.
- Lara OD, Bayraktar E, Amero P, Ma S, Ivan C, Hu W, Wang Y, Mangala LS, Dutta P, Bhattacharya P, Ashizawa AT, Lopez-Berestein G, Rodriguez-Aguayo C, Sood AK. Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget 11(29):2819-2833, 2020. e-Pub 2020. PMID: 32754300.
- Attia YM, Shouman SA, Salama SA, Ivan C, Elsayed AM, Amero P, Rodriguez-Aguayo C, Lopez-Berestein G. Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer. Int J Mol Sci 21(8), 2020. e-Pub 2020. PMID: 32340192.
- Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, Mishra MK, Tahiri A, Zhao W, Nair B, Lu Y, Mangala LS, Rodriguez-Aguayo C, Lopez-Berestein G, Camara AKS, Liang M, Rader JS, Ramchandran R, You M, Sood AK, Kristensen VN, Mills GB, Pradeep S, Chaluvally-Raghavan P. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Rep 29(13):4389-4406.e10, 2019. e-Pub 2019. PMID: 31875548.
- Xu X, Wang Y, Mojumdar K, Zhou Z, Jeong KJ, Mangala LS, Yu S, Tsang YH, Rodriguez-Aguayo C, Lu Y, Lopez-Berestein G, Sood AK, Mills GB, Liang H. A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. J Clin Invest 129(12):5343-5356, 2019. e-Pub 2019. PMID: 31682236.
- Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, Lopez-Berestein G, Le XF, Ahmed AA, Piwnica-Worms H, Sood AK, Bast RC, Lu Z. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clin Cancer Res 25(18):5702-5716, 2019. e-Pub 2019. PMID: 31391192.
- Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene 38(33):6095-6108, 2019. e-Pub 2019. PMID: 31289363.
- Amano H, Chaudhury A, Rodriguez-Aguayo C, Lu L, Akhanov V, Catic A, Popov YV, Verdin E, Johnson H, Stossi F, Sinclair DA, Nakamaru-Ogiso E, Lopez-Berestein G, Chang JT, Neilson JR, Meeker A, Finegold M, Baur JA, Sahin E. Telomere Dysfunction Induces Sirtuin Repression that Drives Telomere-Dependent Disease. Cell Metab 29(6):1274-1290.e9, 2019. e-Pub 2019. PMID: 30930169.
- Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther 18(5):969-979, 2019. e-Pub 2019. PMID: 30926640.
- Mokhlis HA, Bayraktar R, Kabil NN, Caner A, Kahraman N, Rodriguez-Aguayo C, Zambalde EP, Sheng J, Karagoz K, Kanlikilicer P, Abdel Aziz AAH, Abdelghany TM, Ashour AA, Wong S, Gatza ML, Calin GA, Lopez-Berestein G, Ozpolat B. The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. Mol Ther Nucleic Acids 14:301-317, 2019. e-Pub 2019. PMID: 30654191.
- Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK. Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. Mol Cancer Ther 18(2):421-436, 2019. e-Pub 2019. PMID: 30420565.
- Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine 40:290-304, 2019. e-Pub 2019. PMID: 30655206.
- Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK. PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther 18(1):162-172, 2019. e-Pub 2019. PMID: 30305341.
- Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine 38:100-112, 2018. e-Pub 2018. PMID: 30487062.
- González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martín-Salvago MD, Luque RJ, Rosa-Garrido C, Landeira D, Quintana-Romero M, Rosato RR, García MA, Ramirez-Tortosa CL, Kim H, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Lorente JA, Sánchez-Rovira P, Chang JC, Granados-Principal S. Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling. Clin Cancer Res 24(22):5697-5709, 2018. e-Pub 2018. PMID: 30012564.
- Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24(20):5072-5084, 2018. e-Pub 2018. PMID: 30084832.
- Bayraktar R, Ivan C, Bayraktar E, Kanlikilicer P, Kabil NN, Kahraman N, Mokhlis HA, Karakas D, Rodriguez-Aguayo C, Arslan A, Sheng J, Wong S, Lopez-Berestein G, Calin GA, Ozpolat B. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. Clin Cancer Res 24(17):4225-4241, 2018. e-Pub 2018. PMID: 29748184.
- Gharpure KM, Pradeep S, Sans M, Rupaimoole R, Ivan C, Wu SY, Bayraktar E, Nagaraja AS, Mangala LS, Zhang X, Haemmerle M, Hu W, Rodriguez-Aguayo C, McGuire M, Mak CSL, Chen X, Tran MA, Villar-Prados A, Pena GA, Kondetimmanahalli R, Nini R, Koppula P, Ram P, Liu J, Lopez-Berestein G, Baggerly K, S Eberlin L, Sood AK. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9(1):2923, 2018. e-Pub 2018. PMID: 30050129.
- Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK. Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78(12):3233-3242, 2018. e-Pub 2018. PMID: 29661830.
- Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight 3(11), 2018. e-Pub 2018. PMID: 29889661.
- Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 3(11), 2018. e-Pub 2018. PMID: 29889660.
- Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, Lawhon SE, Siverly AN, Su X, Li J, Xie X, Cheng X, Liu LC, Chang HW, Chiang SF, Lopez-Berestein G, Sood AK, Chen J, You MJ, Sun SC, Liang H, Huang Y, Yang X, Sun D, Sun Y, Hung MC, Ma L. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Rep 23(3):823-837, 2018. e-Pub 2018. PMID: 29669287.
- Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28(4):432-447, 2018. e-Pub 2018. PMID: 29567676.
- Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 37(1):107-124, 2018. e-Pub 2018. PMID: 29243000.
- Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 9(1):476, 2018. e-Pub 2018. PMID: 29396402.
- Velazquez-Torres G, Shoshan E, Ivan C, Huang L, Fuentes-Mattei E, Paret H, Kim SJ, Rodriguez-Aguayo C, Xie V, Brooks D, Jones SJM, Robertson AG, Calin G, Lopez-Berenstein G, Sood A, Bar-Eli M. A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun 9(1):461, 2018. e-Pub 2018. PMID: 29386624.
- Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, Lopez-Berestein G, Landis MD, Rosato RR, Dave B, Wong S, Marchetti D, Sood AK, Chang JC. HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports 10(1):212-227, 2018. e-Pub 2018. PMID: 29249663.
- Lu Y, Hu Z, Mangala LS, Stine ZE, Hu X, Jiang D, Xiang Y, Zhang Y, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, DeMarzo AM, Sood AK, Zhang L, Dang CV. MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78(1):64-74, 2018. e-Pub 2018. PMID: 29180471.
- Kanlikilicer P, Ozpolat B, Aslan B, Bayraktar R, Gurbuz N, Rodriguez-Aguayo C, Bayraktar E, Denizli M, Gonzalez-Villasana V, Ivan C, Lokesh GLR, Amero P, Catuogno S, Haemmerle M, Wu SY, Mitra R, Gorenstein DG, Volk DE, de Franciscis V, Sood AK, Lopez-Berestein G. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol Ther Nucleic Acids 9:251-262, 2017. e-Pub 2017. PMID: 29246304.
- Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, Coleman RL, Sood AK. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP). Oncogene. e-Pub 2017. PMID: 29059175.
- Hu Q, Hisamatsu T, Haemmerle M, Cho MS, Pradeep S, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Wong STC, Sood AK, Afshar-Kharghan V. Role of Platelet-Derived Tgfβ1 in the Progression of Ovarian Cancer. Clin Cancer Res 23(18):5611-5621, 2017. e-Pub 2017. PMID: 28611202.
- Haemmerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, Lyons YM, Nagaraja AS, Dood RL, Wen Y, Mangala LS, Hansen JM, Rupaimoole R, Gharpure KM, Rodriguez-Aguayo C, Yim SY, Lee JS, Ivan C, Hu W, Lopez-Berestein G, Wong ST, Karlan BY, Levine DA, Liu J, Afshar-Kharghan V, Sood AK. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat Commun 8(1):310, 2017. e-Pub 2017. PMID: 28827520.
- Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 2(16), 2017. e-Pub 2017. PMID: 28814667.
- Tseng JH, Bisogna M, Hoang LN, Olvera N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Levine DA, Jelinic P. miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. Sci Rep 7(1):3614, 2017. e-Pub 2017. PMID: 28620240.
- Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA. Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res 23(11):2891-2904, 2017. e-Pub 2017. PMID: 27903673.
- Wagner MJ, Mitra R, McArthur MJ, Baze W, Barnhart K, Wu SY, Rodriguez-Aguayo C, Zhang X, Coleman RL, Lopez-Berestein G, Sood AK. Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA). Mol Cancer Ther 16(6):1114-1123, 2017. e-Pub 2017. PMID: 28265009.
- Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodríguez-Aguayo C, López-Berestein G, Ju-Seog L, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M. HSP70 inhibition synergistically enhances the effects of magnetic fluid hyperthermia in ovarian cancer. Mol Cancer Ther 16(5):966-976, 2017. e-Pub 2017. PMID: 28223424.
- Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Okugawa Y, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafà R, Spizzo R, Nicoloso MS, Paranjape AN, Shariati M, Tiron A, Yeh JJ, Teruel-Montoya R, Xiao L, Melo SA, Menter D, Jiang ZQ, Flores ER, Negrini M, Goel A, Bar-Eli M, Mani SA, Liu CG, Lopez-Berestein G, Berindan-Neagoe I, Esteller M, Kopetz S, Lanza G, Calin GA. N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biol 18(1):98, 2017. e-Pub 2017. PMID: 28535802.
- Rabinowicz N, Mangala LS, Brown KR, Checa-Rodriguez C, Castiel A, Moskovich O, Zarfati G, Trakhtenbrot L, Levy-Barda A, Jiang D, Rodriguez-Aguayo C, Pradeep S, van Praag Y, Lopez-Berestein G, David A, Novikov I, Huertas P, Rottapel R, Sood AK, Izraeli S. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. Oncotarget 8(16):27380-27392, 2017. e-Pub 2017. PMID: 28423708.
- H Rashed M, Bayraktar E, K Helal G, Abd-Ellah MF, Amero P, Chavez-Reyes A, Rodriguez-Aguayo C. Exosomes: From Garbage Bins to Promising Therapeutic Targets. Int J Mol Sci 18(3):538, 2017. e-Pub 2017. PMID: 28257101.
- Rashed MH, Kanlikilicer P, Rodriguez-Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B, Denizli M, Mitra R, Ozpolat B, Calin GA, Sood AK, Abd-Ellah MF, Helal GK, Berestein GL. Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget 8(12):20145-20164, 2017. e-Pub 2017. PMID: 28423620.
- Denizli M, Aslan B, Mangala LS, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK. Chitosan Nanoparticles for miRNA Delivery. Methods Mol Biol 1632:219-230, 2017. e-Pub 2017. PMID: 28730442.
- Rodriguez-Aguayo C, Monroig PDC, Redis RS, Bayraktar E, Almeida MI, Ivan C, Fuentes-Mattei E, Rashed MH, Chavez-Reyes A, Ozpolat B, Mitra R, Sood AK, Calin GA, Lopez-Berestein G. Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov 3:17029, 2017. e-Pub 2017. PMID: 28904816.
- Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Res 76(24):7194-7207, 2016. e-Pub 2016. PMID: 27742688.
- Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, Shim J, Dorniak PL, Mangala LS, Petrillo M, Petyuk VA, Schepmoes AA, Shukla AK, Torres-Lugo M, Lee JS, Rodland KD, Fagotti A, Lopez-Berestein G, Li C, Sood AK. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Rep 17(6):1621-1631, 2016. e-Pub 2016. PMID: 27806300.
- Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK. Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight 1(17):e87754, 2016. e-Pub 2016. PMID: 27777972.
- Seviour EG, Sehgal V, Mishra D, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Lee JS, Sood AK, Kim MP, Mills GB, Ram PT. Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene. e-Pub 2016. PMID: 27669434.
- Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Yau C, Sood AK, Motohara T, Knapp S, Ahmed AA. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell 30(2):273-89, 2016. e-Pub 2016. PMID: 27478041.
- Rupaimoole R, Ivan C, Yang D, Gharpure KM, Wu SY, Pecot CV, Previs RA, Nagaraja AS, Armaiz-Pena GN, McGuire M, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Zhang W, Lopez-Berestein G, Calin GA, Sood AK. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene 35(33):4312-20, 2016. e-Pub 2016. PMID: 26725326.
- Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER. ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell 29(6):874-88, 2016. e-Pub 2016. PMID: 27300436.
- Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, Mills GB. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Rep 15(7):1493-504, 2016. e-Pub 2016. PMID: 27160903.
- Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Gharpure KM, Pradeep S, Zand B, Previs RA, Hansen JM, Ivan C, Rodriguez-Aguayo C, Yang P, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Sustained Adrenergic Signaling Leads to Increased Metastasis in Ovarian Cancer via Increased PGE2 Synthesis. Oncogene 35(18):2390-7, 2016. e-Pub 2016. PMID: 26257064.
- Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget 7(15):20825-39, 2016. e-Pub 2016. PMID: 26959114.
- Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun 7:11169, 2016. e-Pub 2016. PMID: 27041221.
- Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, Rodriguez-Aguayo C, Ivan C, Ram P, Sehgal V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. Clin Cancer Res 22(7):1713-24, 2016. e-Pub 2016. PMID: 26581245.
- Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget 7(12):15093-104, 2016. e-Pub 2016. PMID: 26918603.
- Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Beretta L. Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology 63(3):864-79, 2016. e-Pub 2016. PMID: 26599259.
- Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, Kinnebrew G, Han L, Atlasi Y, Cheung LH, Huang GY, Monroig P, Ramirez MS, Catela Ivkovic T, Van L, Ling H, Gafà R, Kapitanovic S, Lanza G, Bankson JA, Huang P, Lai SY, Bast RC, Rosenblum MG, Radovich M, Ivan M, Bartholomeusz G, Liang H, Fraga MF, Widger WR, Hanash S, Berindan-Neagoe I, Lopez-Berestein G, Ambrosio ALB, Gomes Dias SM, Calin GA. Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Mol Cell 61(4):520-34, 2016. e-Pub 2016. PMID: 26853146.
- Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot CV, Pecot C, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene 35(6):691-701, 2016. e-Pub 2016. PMID: 25639871.
- Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, Kinnebrew G, Han L, Atlasi Y, Cheung LH, Huang GY, Monroig P, Ramirez MS, Catela Ivkovic T, Van L, Ling H, Gafà R, Kapitanovic S, Lanza G, Bankson JA, Huang P, Lai SY, Bast RC, Rosenblum MG, Radovich M, Ivan M, Bartholomeusz G, Liang H, Fraga MF, Widger WR, Hanash S, Berindan-Neagoe I, Lopez-Berestein G, Ambrosio ALB, Gomes Dias SM, Calin GA. Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Mol Cell 61(4):640, 2016. e-Pub 2016. PMID: 28934601.
- Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst 108(6):djv426, 2016. e-Pub 2016. PMID: 26819345.
- Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, Lopez-Berestein G, Jeong W, Park IS, Park YN, Sood AK, Mills GB, Lee JS. Yes-Associated Protein 1 and Transcriptional Coactivator with PDZ-Binding Motif Activate the Mammalian Target of Rapamycin Complex 1 Pathway by Regulating Amino Acid Transporters in Hepatocellular Carcinoma. Hepatology 63(1):159-72, 2016. e-Pub 2016. PMID: 26389641.
- Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NMZ, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Rep 13(11):2395-402, 2015. e-Pub 2015. PMID: 26686630.
- Shields BB, Pecot CV, Gao H, McMillan E, Potts M, Nagel C, Purinton S, Wang Y, Ivan C, Kim HS, Borkowski RJ, Khan S, Rodriguez-Aguayo C, Lopez-Berestein G, Lea J, Gazdar A, Baggerly KA, Sood AK, White MA. A Genome-scale Screen Reveals Context-Dependent Ovarian Cancer Sensitivity to miRNA Overexpression. Mol Syst Biol 11(12):842, 2015. e-Pub 2015. PMID: 26655797.
- Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell 28(5):610-22, 2015. e-Pub 2015. PMID: 26481148.
- Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W. Augmentation of Response to Chemotherapy by MicroRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. J Natl Cancer Inst 107(7), 2015. e-Pub 2015. PMID: 25995442.
- Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G. The ZNF304-Integrin Axis Protects Against Anoikis in Cancer. Nat Commun 6:7351, 2015. e-Pub 2015. PMID: 26081979.
- Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Del C Monroig P, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, Calin G, Sood AK, Lopez-Berestein G. Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clin Cancer Res 21(9):2127-37, 2015. e-Pub 2015. PMID: 25595279.
- Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X. TP53 Loss Creates Therapeutic Vulnerability in Colorectal Cancer. Nature 520(7549):697-701, 2015. e-Pub 2015. PMID: 25901683.
- Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, Sood AK, Lopez-Berestein G. Adrenergic Regulation of Monocyte Chemotactic Protein 1 Leads to Enhanced Macrophage Recruitment and Ovarian Carcinoma Growth. Oncotarget 6(6):4266-73, 2015. e-Pub 2015. PMID: 25738355.
- Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Ji P, Chen K, Sood AK, Mezzanzanica D, Liu J, Sun B, Zhang W. MiR-506 Inhibits Multiple Targets in the Epithelial-to-Mesenchymal Transition Network and is Associated with good Prognosis in Epithelial Ovarian Cancer. J Pathol 235(1):25-36, 2015. e-Pub 2015. PMID: 25230372.
- Moss TJ, Luo Z, Seviour EG, Sehgal V, Lu Y, Hill SM, Rupaimoole R, Lee JS, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Azencott R, Gray JW, Mukherjee S, Mills GB, Ram PT. Genome-Wide Perturbations by miRNAs Map onto Functional Cellular Pathways, Identifying Regulators of Chromatin Modifiers. NPJ Syst Biol Appl 1:15001, 2015. e-Pub 2015. PMID: 28725457.
- Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, Le XF, Bast RC. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. PLoS One 10(7):e0131833, 2015. e-Pub 2015. PMID: 26146988.
- Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB. Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. Cancer Cell 26(6):863-79, 2014. e-Pub 2014. PMID: 25490449.
- Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, Hu Y, Ang KK, Chen J, Ma L. miR-205 Acts as a Tumour Radiosensitizer by Targeting ZEB1 and Ubc13. Nat Commun 5:5671, 2014. e-Pub 2014. PMID: 25476932.
- Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK. Therapeutic Silencing of KRAS using Systemically Delivered siRNAs. Mol Cancer Ther 13(12):2876-85, 2014. e-Pub 2014. PMID: 25281617.
- Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, Rashed MH, Aslan B, Erdogan MA, Gutierrez-Puente Y, Ozpolat B, Reuben JM, Sood AK, Logsdon C, Lopez-Berestein G. Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin-Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther 13(11):2583-94, 2014. e-Pub 2014. PMID: 25193509.
- Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, Nagaraja AS, Armaiz-Pena GN, McGuire M, Zand B, Dalton HJ, Filant J, Miller JB, Lu C, Sadaoui NC, Mangala LS, Taylor M, van den Beucken T, Koch E, Rodriguez-Aguayo C, Huang L, Bar-Eli M, Wouters BG, Radovich M, Ivan M, Calin GA, Zhang W, Lopez-Berestein G, Sood AK. Hypoxia-Mediated Downregulation of miRNA Biogenesis Promotes Tumour Progression. Nat Commun 5:5202, 2014. e-Pub 2014. PMID: 25351346.
- Zhaorigetu S, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G, Walton BL. Delivery of Negatively Charged Liposomes into the Atherosclerotic Plaque of Apolipoprotein E-Deficient Mouse Aortic Tissue. J Liposome Res 24(3):182-90, 2014. e-Pub 2014. PMID: 24443972.
- Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK. Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. Cancer Cell 26(1):77-91, 2014. e-Pub 2014. PMID: 25026212.
- Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath D. Metabolic Shifts Toward Glutamine Regulate Tumor Growth, Invasion and Bioenergetics in Ovarian Cancer. Mol Syst Biol 10:728, 2014. e-Pub 2014. PMID: 24799285.
- Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN, Eblen ST. EDD Enhances Cell Survival and Cisplatin Resistance and is a Therapeutic Target for Epithelial Ovarian Cancer. Carcinogenesis 35(5):1100-9, 2014. e-Pub 2014. PMID: 24379240.
- Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan V. Autocrine Effects of Tumor-Derived Complement. Cell Rep 6(6):1085-95, 2014. e-Pub 2014. PMID: 24613353.
- Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-Phosphorodithioate-Modified siRNAs Show Increased Loading into the RISC Complex and Enhanced Anti-Tumour Activity. Nat Commun 5:3459, 2014. e-Pub 2014. PMID: 24619206.
- Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA. Therapeutic Synergy Between MicroRNA and siRNA in Ovarian Cancer Treatment. Cancer Discov 3(11):1302-15, 2013. e-Pub 2013. PMID: 24002999.
- Tekedereli I, Alpay SN, Akar U, Yuca E, Ayugo-Rodriguez C, Han HD, Sood AK, Lopez-Berestein G, Ozpolat B. Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer. Mol Ther Nucleic Acids 2:e121, 2013. e-Pub 2013. PMID: 24022053.
- Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JS. Tat-Activating Regulatory DNA-Binding Protein Regulates Glycolysis in Hepatocellular Carcinoma by Regulating the Platelet Isoform of Phosphofructokinase Through MicroRNA 520. Hepatology 58(1):182-91, 2013. e-Pub 2013. PMID: 23389994.
- Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B Mediates Platinum Resistance in Ovarian Cancer. J Clin Invest 123(5):2119-30, 2013. e-Pub 2013. PMID: 23585472.
- Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G. Enhancing Chemotherapy Response with Sustained EphA2 Silencing Using Multistage Vector Delivery. Clin Cancer Res 19(7):1806-15, 2013. e-Pub 2013. PMID: 23386691.
- Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer. Clin Cancer Res 19(4):809-20, 2013. e-Pub 2013. PMID: 23344261.
- Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K, Zhang W. Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. Cancer Cell 23(2):186-99, 2013. e-Pub 2013. PMID: 23410973.
- Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Shazhad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK. Src Activation by β-Adrenoreceptors is a Key Switch for Tumour Metastasis. Nat Commun 4:1403, 2013. e-Pub 2013. PMID: 23360994.
- Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. Cystathionine Beta-Synthase (CBS) Contributes to Advanced Ovarian Cancer Progression and Drug Resistance. PLoS One 8(11):e79167, 2013. e-Pub 2013. PMID: 24236104.
- Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK. Tumour Angiogenesis Regulation by the miR-200 Family. Nat Commun 4:2427, 2013. e-Pub 2013. PMID: 24018975.
- Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 Mediates Dox Resistance in Breast Cancer by Enhancing DNA Repair. Carcinogenesis 33(10):1843-53, 2012. e-Pub 2012. PMID: 22581827.
- Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK. Targeting the PELP1-KDM1 Axis as a Potential Therapeutic Strategy for Breast Cancer. Breast Cancer Res 14(4):R108, 2012. e-Pub 2012. PMID: 22812534.
- Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane--Resistant Ovarian Cancer. Clin Cancer Res 17(11):3716-26, 2011. e-Pub 2011. PMID: 21512144.
- Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R. Enhancing Chemotherapy Response with Bmi-1 Silencing in Ovarian Cancer. PLoS One 6(3):e17918, 2011. e-Pub 2011. PMID: 21445297.
- Samuel S, Gaur P, Fan F, Xia L, Gray MJ, Dallas NA, Bose D, Rodriguez-Aguayo C, Lopez-Berestein G, Plowman G, Bagri A, Sood AK, Ellis LM. Neuropilin-2 Mediated β-Catenin Signaling and Survival in Human Gastro-Intestinal Cancer Cell Lines. PLoS One 6(10):e23208, 2011. e-Pub 2011. PMID: 22028766.
- Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. c-Jun-NH2-Kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer. Clin Cancer Res 16(1):184-94, 2010. e-Pub 2010. PMID: 20028751.
Invited Articles
- Bozgeyik E, Bayraktar E, Chavez-Reyes A, Rodriguez-Aguayo C. OncoLncs: Long Non-Coding RNAs with Oncogenic Functions. Mol Biol 5(3), 2016. e-Pub 2016.
- Bayraktar E, Rodriguez-Aguayo C. MicroRNA Therapeutics: Basic Principles, Barriers and Perspectives. BAOJ Cancer Res Ther 1(3), 2015. e-Pub 2015.
Review Articles
- Çakan, E, Lara, OD, Szymanowska, A, Bayraktar, E, Chavez-Reyes, A, Lopez Berestein, G, Amero, P, Rodriguez-Aguayo, C. Therapeutic Antisense Oligonucleotides in Oncology. Cancers 16(17), 2024. e-Pub 2024. PMID: 39272802.
- Castillo Martinez, M, M. Elsayed, A, Lopez Berestein, G, Amero, P, Rodriguez-Aguayo, C. An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer. Non-coding RNA 9(6), 2023. e-Pub 2023. PMID: 37987366.
- Szymanowski, W, Szymanowska, A, Bielawska, A, Lopez Berestein, G, Rodriguez-Aguayo, C, Amero, P. Aptamers as Potential Therapeutic Tools for Ovarian Cancer. Cancers 15(21), 2023. e-Pub 2023. PMID: 37958473.
- Szymanowska, A, Rodriguez-Aguayo, C, Lopez Berestein, G, Amero, P. Non-Coding RNAs. Non-coding RNA 9(5), 2023. e-Pub 2023. PMID: 37736898.
- Karadeniz Saygılı, S, Szymanowska, A, Lopez Berestein, G, Rodriguez-Aguayo, C, Amero, P. Aptamers as Insights for Targeting SARS-CoV-2. Biologics 3(2):116-137, 2023. e-Pub 2023.
- Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, Amero P, Rodriguez-Aguayo C. Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update. Noncoding RNA 9(2), 2023. e-Pub 2023. PMID: 37104009.
- Amero P, Khatua S, Rodriguez-Aguayo C, Lopez-Berestein G. Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33050158.
- Elsayed AM, Amero P, Salama SA, Abdelaziz AH, Lopez-Berestein G, Rodriguez-Aguayo C. Back to the Future: Rethinking the Great Potential of lncRNAS for Optimizing Chemotherapeutic Response in Ovarian Cancer. Cancers (Basel) 12(9), 2020. e-Pub 2020. PMID: 32854207.
- Shahzad MM, Shin YH, Matsuo K, Lu C, Nishimura M, Shen DY, Kang Y, Hu W, Mora EM, Rodriguez-Aguayo C, Kapur A, Bottsford-Miller J, Lopez-Berestein G, Rajkovic A, Sood AK. Biological Significance of HORMA Domain Containing Protein 1 (HORMAD1) in Epithelial Ovarian Carcinoma. Cancer Lett 330(2):123-9, 2013. e-Pub 2013. PMID: 22776561.
Other Articles
- Kanlikilicer, P, Bayraktar, R, Denizli, M, Rashed, MH, Ivan, C, Aslan, B, Mitra, R, Karagoz, K, Bayraktar, E, Zhang, X, Rodriguez-Aguayo, C, El-Arabey, AA, Kahraman, N, Baydogan, S, Ozkayar, O, Gatza, ML, Ozpolat, B, Calin, GA, Sood, AK, Lopez Berestein, G Corrigendum to Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer (eBioMedicine (2018) 38 (100–112), (S2352396418304973), (10.1016/j.ebiom.2018.11.004)). EBioMedicine 111, 2025. PMID: 39637523.
- Rodriguez-Aguayo, C, del C Monroig, P, Redis, RS, Bayraktar, E, Almeida, MD, Ivan, C, Fuentes-Mattei, E, Rashed, MH, Chavez-Reyes, A, Ozpolat, B, Mitra, R, Sood, AK, Calin, GA, Lopez Berestein, G Author Correction. Cell Discovery 9(1), 2023. PMID: 37940695.
- George, J, Li, Y, Kadamberi, IP, Parashar, D, Tsaih, SW, Gupta, P, Geethadevi, A, Chen, C, Ghosh, C, Sun, Y, Mittal, S, Ramchandran, R, Rui, H, Lopez Berestein, G, Rodriguez-Aguayo, C, Leone, G, Rader, JS, Sood, AK, Dey, M, Pradeep, S, Chaluvally-Raghavan, P Erratum. Cell Reports 42(3), 2023. PMID: 36884347.
- Moreno-Smith, M, Halder, J, Meltzer, PS, Gonda, TA, Mangala, LS, Rupaimoole, R, Lu, C, Nagaraja, AS, Gharpure, K, Kang, Y, Rodriguez-Aguayo, C, Vivas-Mejia, P, Zand, B, Schmandt, R, Wang, H, Langley, RR, Jennings, NB, Ivan, C, Coffin, JE, Armaiz, GN, Bottsford-Miller, J, Kim, SB, Halleck, MS, Hendrix, MJ, Bornman, W, Bar Eli, M, Lee, J, Siddik, ZH, Lopez Berestein, G, Sood, AK Erratum. Journal of Clinical Investigation 131(7), 2021. PMID: 33792569.
Book Chapters
- Oncul, S, Amero, P, Rodriguez-Aguayo, C, Sood, AK, Calin, GA, Lopez Berestein, G. RNA delivery for cancer gene therapy, 375-424, 2022.
- Mangala, LS, Rodriguez-Aguayo, C, Bayraktar, E, Jennings, NB, Lopez Berestein, G, Sood, AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models, 157-168, 2021.
- Jiang D, Mangala LS, Rodriguez-Aguayo C, Gorenstein DG, Lopez-Berestein G, Sood AK. Targeting approaches for nanoparticles. In: Nanoparticles for Biotherapeutic Delivery, 2015.
- Rodriguez-Aguayo, C, Chavez-Reyes, A, Lopez-Berestein, Sood G, AK. RNAi in Cancer Therapy. In: Advanced Delivery and Therapeutic Applications of RNAi, 271-307, 2013.
- Kanlikilicer P, Rashed MH, Ozpolat B, Rodriguez-Aguayo C, Sood AK, Calin GA, Lopez-Berestein AG. The “EX” and the “SOMA”: How They Communicate. In: Nano-Oncologicals: New Targeting and Delivery Approaches Springer. Springer, 2013.
Letters to the Editor
- Chakraborty, D, Gutierrez-Chakraborty, E, Rodriguez-Aguayo, C, Başağaoğlu, H, Lopez Berestein, G, Amero, P. Discovering genetic biomarkers for targeted cancer therapeutics with eXplainable Artificial Intelligence. Cancer Communications 44: 584-588, 2024.
Patents
- Lopez-Berestein, Gabriel. DNA Aptamers and Use Thereof for the Treatment of Cancer. Patent Number: PCT/US20 19/066654.
Patient Reviews
CV information above last modified July 22, 2026